Increased expression of osteopontin in patients with triple‐negative breast cancer

Wang, X.; Lan, Chao; Ma, Guansheng; Chen, L.; Tian, Bin; Zang, Y.; Sun, Jingyu

doi:10.1111/j.1365-2362.2008.01956.x

Cited by 52 publications

(35 citation statements)

References 31 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have previously demonstrated that the triplenegative phenotype of breast carcinomas is significantly associated with osteopontin (OPN) overexpression (Wang et al 2008). Additionally, studies have shown that the basal-like/triple-negative subtype is also associated with P53 overexpression (Tuck et al 1997;Turner et al 2004;Parikh et al 2008a, b).…”

Section: Discussionmentioning

confidence: 98%

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

Xiao

Lan

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

Xiao

Lan

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The finding of higher osteopontin and ON expression in bone-metastasizing human prostate cancer tissue highlights the potential prognostic value of osteopontin and other bone-resident proteins in cancer [207, 208]. Osteopontin levels are also higher in triple-negative breast cancers [209]. Periostin is another secreted stromal protein overexpressed in many cancers including prostate, breast, colon, ovarian, pancreatic, and melanoma stroma.…”

Section: Secreted Proteinsmentioning

confidence: 99%

Insidious Changes in Stromal Matrix Fuel Cancer Progression

Miles

Sikes

2014

Molecular Cancer Research

View full text Add to dashboard Cite

Reciprocal interactions between tumor and stromal cells propel cancer progression and metastasis. An understanding of the complex contributions of the tumor stroma to cancer progression necessitates a careful examination of the extracellular matrix (ECM), which is largely synthesized and modulated by Cancer Associated Fibroblasts (CAFs). This structurally supportive meshwork serves as a signaling scaffold for a myriad of biological processes and responses favoring tumor progression. The ECM is a repository for growth factors and cytokines that promote tumor growth, proliferation, and metastasis through diverse interactions with soluble and insoluble ECM components. Growth factors activated by proteases are involved in the initiation of cell signaling pathways essential to invasion and survival. Various transmembrane proteins produced by the cancer stroma bind the collagen and fibronectin-rich matrix to induce proliferation, adhesion and migration of cancer cells, as well as protease activation. Integrins are critical liaisons between tumor cells and the surrounding stroma, and with their mechano-sensing ability induce cell signaling pathways associated with contractility and migration. Proteoglycans also bind and interact with various matrix proteins in the tumor microenvironment to promote cancer progression. Together, these components function to mediate crosstalk between tumor cells and fibroblasts ultimately to promote tumor survival and metastasis. These stromal factors, which may be expressed differentially according to cancer stage, have prognostic utility and potential. In this review, we examine changes in the ECM of cancer associated fibroblasts induced through carcinogenesis, and the implications of these changes on cancer progression.

show abstract

“…Wang et al [132] evaluated osteopontin protein expression in TNBC to determine if they correlated with clinicopathological parameters on 117 breast carcinoma tissue samples, and then assessed the mean value of osteopontin expression against TN-status and clinicopathological parameters. Of the 239 patients in the study, 47 were classified as triple negative.…”

Section: Altered Expression Of Several Oncogenic Proteins and Tumomentioning

confidence: 99%

ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Chen

Russo

2009

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

117

104

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer patients and are more prevalent among young African, African-American and Latino women patients. The currently available ER-targeted and Her-2-based therapies are not effective for treating TNBC. Recent studies have revealed a number of novel features of TNBC. In the present work, we comprehensively addressed these features and discussed potential therapeutic approaches based on these features for TNBC, with particular focus on: 1) the pathological features of TNBC/basal-like breast cancer; 2) E2/ERβ – mediated signaling pathways; 3) G-protein coupling receptor-30/epithelial growth factor receptor (GPCR-30/EGFR) signaling pathway; 4) interactions of ERβ with breast cancer 1/2 (BRCA1/2); 5) chemokine CXCL8 and related chemokines; 6) altered microRNA signatures and suppression of ERα expression/ERα-signaling by micro-RNAs; 7) altered expression of several pro-oncongenic and tumor suppressor proteins; and 8) genotoxic effects caused by oxidative estrogen metabolites. Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC.

show abstract

Increased expression of osteopontin in patients with triple‐negative breast cancer

Abstract: Patients with osteopontin overexpression develop predominantly triple-negative tumours. Osteopontin overexpression is associated with tumour aggressiveness and poor prognosis.

Cited by 52 publications

References 31 publications

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

Insidious Changes in Stromal Matrix Fuel Cancer Progression

ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Contact Info

Product

Resources

About